Howard A Burris 3rd
Overview
Explore the profile of Howard A Burris 3rd including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
173
Citations
9110
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gainor J, Patel M, Weber J, Gutierrez M, Bauman J, Clarke J, et al.
Cancer Discov
. 2024 Aug;
14(11):2209-2223.
PMID: 39115419
mRNA-4157 (V940) is an individualized neoantigen therapy targeting up to 34 patient-specific tumor neoantigens to induce T-cell responses and potentiate antitumor activity. We report mechanistic insights into the immunogenicity of...
2.
Oh D, He A, Bouattour M, Okusaka T, Qin S, Chen L, et al.
Lancet Gastroenterol Hepatol
. 2024 Jun;
9(8):694-704.
PMID: 38823398
Background: In the preplanned interim analysis of the TOPAZ-1 study, durvalumab plus gemcitabine-cisplatin significantly improved overall survival versus placebo plus gemcitabine-cisplatin in participants with advanced biliary tract cancer. We aimed...
3.
Subbiah V, Gouda M, Ryll B, Burris 3rd H, Kurzrock R
CA Cancer J Clin
. 2024 May;
74(5):433-452.
PMID: 38814103
Tumor-agnostic therapies represent a paradigm shift in oncology by altering the traditional means of characterizing tumors based on their origin or location. Instead, they zero in on specific genetic anomalies...
4.
Burris 3rd H, Okusaka T, Vogel A, Lee M, Takahashi H, Breder V, et al.
Lancet Oncol
. 2024 May;
25(5):626-635.
PMID: 38697156
Background: In the ongoing, randomised, double-blind phase 3 TOPAZ-1 study, durvalumab, a PD-L1 inhibitor, plus gemcitabine and cisplatin was associated with significant improvements in overall survival compared with placebo, gemcitabine,...
5.
Mayer E, Tayob N, Ren S, Savoie J, Spigel D, Burris 3rd H, et al.
Breast Cancer Res Treat
. 2023 Nov;
204(1):123-132.
PMID: 38019444
Purpose: Metronomic chemotherapy has the potential to offer tumor control with reduced toxicity when compared to standard dose chemotherapy in patients with metastatic breast cancer. As metronomic chemotherapy may target...
6.
Subbiah V, Burris 3rd H, Kurzrock R
Cancer
. 2023 Nov;
130(2):186-200.
PMID: 37934000
The landscape of cancer therapy has been transformed by advances in clinical next-generation sequencing, genomically targeted therapies, and immunotherapies. Well designed clinical trials and efficient clinical trial conduct are crucial...
7.
Burris 3rd H
HCA Healthc J Med
. 2023 Jul;
1:321-323.
PMID: 37426836
Description Cancer patients need access to promising investigational therapies, available only through clinical trials, and the emergence of COVID-19 and the resulting pandemic became an emerging threat to fulfilling that...
8.
Schmid P, Cortes J, Joaquim A, Martinez Janez N, Morales S, Diaz-Redondo T, et al.
Breast Cancer Res
. 2023 Jun;
25(1):67.
PMID: 37308971
Background: Xentuzumab is a humanised monoclonal antibody that binds to IGF-1 and IGF-2, neutralising their proliferative activity and restoring inhibition of AKT by everolimus. This study evaluated the addition of...
9.
10.
Gordon L, Karmali R, Kaplan J, Popat R, Burris 3rd H, Ferrari S, et al.
Oncotarget
. 2023 Jan;
14:57-70.
PMID: 36702329
We report an updated analysis from a phase I study of the spleen tyrosine kinase (SYK) and FMS-like tyrosine kinase 3 inhibitor mivavotinib, presenting data for the overall cohort of...